Caplacizumab - Wikipedia
网页Caplacizumab (INN; trade name Cablivi) is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis. [4][5][6][7] This drug was developed by Ablynx NV. [8]
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
网页2019年1月9日 · Caplacizumab, a humanized, bivalent, variable-domain-only immunoglobulin fragment (Nanobody, Ablynx), targets the A1 domain of von Willebrand factor, preventing interaction with the...
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
网页2016年2月11日 · Caplacizumab, an anti–von Willebrand factor humanized single-variable-domain immunoglobulin (Nanobody), inhibits the interaction between ultralarge von Willebrand factor multimers and...
Caplacizumab Uses, Side Effects & Warnings - Drugs.com
网页2024年5月1日 · What is caplacizumab? Caplacizumab is used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Caplacizumab is given together with immunosuppressant medication and plasma exchange (transfusion). Caplacizumab may also be used for purposes not listed in this medication guide.
Caplacizumab: Uses, Interactions, Mechanism of Action
网页2007年11月18日 · Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
网页2021年12月2日 · Caplacizumab is a novel agent approved for the treatment of adult patients with aTTP in conjunction with plasma exchange and immunosuppressive therapies. It works by binding to the A1 domain of von Willebrand factor (VWF), blocking platelets from binding to VWF and aggregating.
Caplacizumab: Dosage, Mechanism/Onset of Action, Half-Life
网页2020年2月10日 · Caplacizumab is a von Willebrand factor (vWF)-directed monoclonal antibody fragment which targets the A1-domain of vWF, inhibiting the interaction between vWF and platelets, reducing both vWF-mediated platelet adhesion and platelet consumption.
FDA approves first therapy for the treatment of adult patients …
网页FDA approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult...
Cablivi for acquired thrombotic thrombocytopenic purpura
网页Caplacizumab is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura, in combination with plasma exchange and immunosuppressive therapy.
Caplacizumab-yhdp Injection: MedlinePlus Drug Information
网页Caplacizumab-yhdp injection is used to treat acquired thrombotic thrombocytopenic purpura (aTTP; a disorder in which the body attacks itself and causes clots, low amounts of platelets and red blood cells, and could cause other serious complications) in combination with plasma exchange therapy and immunosuppressant medications.